Use of genetic mutations for prediction of resistance to pyrazinamide in M. tuberculosis strains
Pyrazinamide (PZA) is a prodrug that is converted to the active compound pyrazinoic acid by the pyrazinamidase enzyme (encoded by the pncA gene in Mycobacterium tuberculosis) at low pH. The phenotypic approach for testing pyrazinamide sensitivity is technically demanding (often associated with poorl...
Main Authors: | Daniela M Cirillo, Paolo Miotto, Stefan Niemann |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2015-01-01
|
Series: | International Journal of Mycobacteriology |
Subjects: | |
Online Access: | http://www.ijmyco.org/article.asp?issn=2212-5531;year=2015;volume=4;issue=5;spage=42;epage=43;aulast=Cirillo;type=0 |
Similar Items
-
Structural Dynamics Behind Clinical Mutants of PncA-Asp12Ala, Pro54Leu, and His57Pro of Mycobacterium tuberculosis Associated With Pyrazinamide Resistance
by: Aamir Mehmood, et al.
Published: (2019-12-01) -
Insights Into Mutations Induced Conformational Changes and Rearrangement of Fe2+ Ion in pncA Gene of Mycobacterium tuberculosis to Decipher the Mechanism of Resistance to Pyrazinamide
by: Asma Sindhoo Nangraj, et al.
Published: (2021-05-01) -
Pyrazinamide resistance in Swedish multidrug-resistant tuberculosis 2003–2013
by: M Mansjö, et al.
Published: (2015-01-01) -
The majority of patients with multidrug-resistant tuberculosis in Sub-Saharan Africa present a concomitant resistance to pyrazinamide
by: Géraldine Daneau, et al.
Published: (2016-01-01) -
Molecular Epidemiological Study of Pyrazinamide-Resistance in Clinical Isolates of Mycobacterium tuberculosis from South India
by: Saroja Veerappan, et al.
Published: (2010-07-01)